Reuters logo
BRIEF-Karyopharm to present updated sign Phase 2 clinical data at European Society of Medical Oncology 2016 annual meeting
October 5, 2016 / 11:02 AM / a year ago

BRIEF-Karyopharm to present updated sign Phase 2 clinical data at European Society of Medical Oncology 2016 annual meeting

Oct 5 (Reuters) - Karyopharm Therapeutics Inc

* Karyopharm to present updated sign Phase 2 clinical data at European Society of Medical Oncology 2016 annual meeting

* Single-Agent Selinexor shows robust clinical benefit,favorable tolerability in heavily pre-treated gynecologic cancer patients

* 49% disease control rate observed in ovarian cancer and 45% observed in endometrial cancer

* Selinexor-Associated adverse events were found to be manageable with supportive care and dose modifications Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below